Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-MET, ABT-700 Vector   (CAT#: GTVCR-WQ228MR)

This product GTVCR-WQ228MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting MET. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Humanized
RefSeq NM_000245.4
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 4233
UniProt ID P08581
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-MET, ABT-700 Vector (GTVCR-WQ228MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ685MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL36RN, BI 655130 Vector Vector BI 655130
GTVCR-WQ477MR IVTScrip™ pSP6-VEE-mRNA-Anti-ADCYAP1R1, AMG-301 Vector Vector AMG-301
GTVCR-WQ2234MR IVTScrip™ pSP6-VEE-mRNA-Anti-PDCD1, PF-06801591 Vector Vector PF-06801591
GTVCR-WQ918MR IVTScrip™ pSP6-VEE-mRNA-Anti-tcdA, CDA 1 Vector Vector CDA 1
GTVCR-WQ2157MR IVTScrip™ pSP6-VEE-mRNA-Anti-TNF, OPRX-106 Vector Vector OPRX-106
GTVCR-WQ100MR IVTScrip™ pT7-VEE-mRNA-Anti-ERBB2, 4D5-8 Vector Vector 4D5-8
GTVCR-WQ249MR IVTScrip™ pSP6-VEE-mRNA-Anti-Aβ15-42, ACC-001 Vector Vector ACC-001
GTVCR-WQ2397MR IVTScrip™ pSP6-VEE-mRNA-Anti-EGFL7, RG7414 Vector Vector RG7414
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW